Search the Newsreel

Organogenesis (ORGO) Stock Price Sinks On Deeper Losses And Margin Crunch

Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

Organogenesis (NASDAQ:ORGO) Issues Quarterly Earnings Results

Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower

Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale

Organogenesis Holdings Inc. has established an at-the-market sales agreement with BTIG, LLC and Citizens JMP Securities, LLC to offer and sell up to $75 million of its Class A common stock. Sales will occur from time to time through the agents on the Nasdaq …

Organogenesis: Q2 Earnings Snapshot

Organogenesis (NASDAQ: ORGO) hit by 58% sales drop and $149M first-half loss

Organogenesis Expects 2026 Revenue Between $179M and $215M

Organogenesis Holdings, Inc. Class A Revenue Breakdown – LSX:A2PA31

Organogenesis Holdings, Inc. Class A (LSX:A2PA31) generated 479.37 million EUR in revenue last year. The Advanced Wound Care segment was the top-performing segment, contributing 452.31 million EUR, an increase from 438.21 million EUR the prior year. The United States was the primary geographic contributor, …

Organogenesis (ORGO) to Release Quarterly Earnings on Thursday

Organogenesis Holdings, Inc. Class A Revenue Breakdown – DUS:2PQ

Organogenesis Holdings, Inc. Class A (2PQ) generated €479.37 million in revenue last year, primarily from its Advanced Wound Care segment, which contributed €452.31 million. The United States was the company's largest revenue source, accounting for the entire €479.37 million. This represents an increase from …

ORGO INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Organogenesis Holdings (ORGO) Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed

Hagens Berman is encouraging Organogenesis Holdings (ORGO) investors who have sustained significant losses to contact their attorneys, as a securities fraud class action has been filed. The lawsuit alleges that Organogenesis improperly billed the federal government for its wound treatment products, Affinity and PuraPly …

Organogenesis Holdings (ORGO) Q1 2026 Earnings: Substantial EPS Miss Pressures Shares - Earnings Acceleration Picks

Organogenesis schedules Aug. 6 results call after market close

ORGO Forecast — Price Target — Prediction for 2027

ORGO Q1 2026 Earnings: EPS Miss of 29.66% Amid Persistent Cost Pressures - Earnings Season Review

Organogenesis Q1 Earnings Call Highlights

Organogenesis posts $53M loss as wound-care sales drop 63%

Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts

Organogenesis to discuss Q1 results and corporate update May 7

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%

Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?

Organogenesis (ORGO) Earnings Date and Reports 2026